Amidst the vibrant biotech landscape in Ghent, Belgium, a new spin-off has emerged with the potential to revolutionize the treatment of cancer and fibrotic diseases. Amalus Therapeutics, a Belgian-Danish company, is at the forefront of developing a novel class of drugs that selectively target corrupt fibroblast cells. This groundbreaking approach holds tremendous promise in improving the outlook for patients battling these challenging conditions.
What sets Amalus Therapeutics apart is their ability to selectively neutralize the “corrupt” fibroblasts while leaving the vital normal fibroblasts unharmed. Fibroblast cells play a detrimental role in difficult-to-treat cancers and fibrosis, creating a protective shield around tumors that hinders the immune system’s ability to effectively combat them. Furthermore, they promote tumor growth, metastasis, and reprogram the immune system to tolerate the tumor.
Christian Stevens, the CEO of Amalus and a professor of Bio-Organic Chemistry at Ghent University, affirms the significance of their innovative approach. By specifically targeting corrupt fibroblasts, they can normalize the tumor environment, inhibit metastasis, and activate the immune system, all while avoiding the detrimental effects on normal fibroblasts that other therapies often cause.
Supported financially by BioInnovation Institute’s Venture Lab acceleration program, Amalus Therapeutics has access to state-of-the-art facilities, knowledge, and an extensive network of investors. This assistance has catapulted the start-up to international recognition, resulting in a nomination for the prestigious ‘One-to-Watch Award’ by the Oxford Business Network.
As Dominic De Groote, the CBO of Amalus, explains, their products not only show standalone effectiveness but also have the potential to enhance the impact of standard therapies in oncology. This makes them highly sought after, offering patients improved outcomes while enabling doctors to build on established treatment strategies.
Amalus Therapeutics, with its pioneering targeted therapy, represents a beacon of hope for patients grappling with the complexities of cancer and fibrotic diseases. With the backing of Ghent University and the thriving Ghent biotech landscape, this innovative spin-off is predicted to chart new horizons in the fight against these challenging conditions.
Frequently Asked Questions
1. What are fibroblast cells?
Fibroblast cells are a type of connective tissue cell that play a crucial role in maintaining the structural integrity of tissues and organs. However, corrupt fibroblasts can contribute to the progression of diseases such as cancer and fibrosis.
2. How does Amalus Therapeutics’ approach differ from other therapies?
Amalus Therapeutics has developed a unique approach that selectively targets corrupt fibroblast cells without harming normal fibroblasts. This sets their therapy apart from conventional treatments that often cause serious side effects.
3. How effective are Amalus Therapeutics’ products?
In animal models, Amalus Therapeutics’ products have demonstrated strong tolerability, normalized tumor environments, inhibited metastases, and activated the immune system’s response. They also have the potential to enhance the effectiveness of standard therapies in oncology.
4. What recognition has Amalus Therapeutics received?
Amalus Therapeutics has been nominated for the ‘One-to-Watch Award’ by the Oxford Business Network, a prestigious recognition bestowed upon promising and innovative startups in the life sciences domain. This highlights the company’s potential and contribution to the field.